IOL Chemicals and Pharmaceuticals share news and announcements
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
Last close ₹164.14down ₹7.22 (4.21%)BSE ₹163.40
Share price at the NSE close on 23 Oct 2026. Previous close ₹171.36.
52-week range of traded prices to 23 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,818 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 28.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 31,10,55637.2% delivered
IOL Chemicals and Pharmaceuticals share news and announcements
716 announcements, routine notices left out, newest first. Page 7 of 15.
Jul 2021
5 Jul · Rating
3 Jul · Legal
The exchange asked on 2 Jul 2021
Jun 2021
14 Jun · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to announcement dated 04-Jun-2021, regarding capacity addition. On basis of above the Company is required to clarify following: 1. Existing capacity utilization;2. Period within which the proposed capacity is to be added;3. Investment required;4. Rationale.The response of the Company is awaited.
May 2021
Apr 2021
Mar 2021
Feb 2021
10 Feb · Board meeting
Dec 2020
Nov 2020
6 Nov · Corporate action
Oct 2020
Sep 2020
28 Sep · Updates
Aug 2020
3 Aug · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited with respect to announcement dated 31-Jul-2020, regarding setting up a new Unit VII for manufacturing of 'Metformin'. On basis of above the Company is required to clarify following: 1. Rationale.The response of the Company is awaited.
Jul 2020
31 Jul · Board meeting
Jun 2020